Review of animal models of prostate cancer bone metastasis

Veterinary Sciences

Volumn 1, Issue 1, 2014, Pages 16-39

  Simmons, Jessica K ^a   Elshafae, Said M ^a   Keller, Evan T ^b   McCauley, Laurie K ^c   Rosol, Thomas J ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

Author keywords

Animal models; Bone metastasis; Prostate cancer

Indexed keywords

EID: 84928392914     PISSN: None     EISSN: 23067381     Source Type: Journal    
DOI: 10.3390/vetsci1010016     Document Type: Review

References (120)

1. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA: Cancer J. Clin. 2013, 63, 11-30
2. Coleman, R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 2006, 12, 6243s-6249s
3. Mehra, R.; Kumar-Sinha, C.; Shankar, S.; Lonigro, R.J.; Jing, X.; Philips, N.E.; Siddiqui, J.; Han, B.; Cao, X.; Smith, D.C.; et al. Characterization of bone metastases from rapid autopsies of prostate cancer patients. Clin. Cancer Res. 2011, 17, 3924-3932
4. Sturge, J.; Caley, M.P.; Waxman, J. Bone metastasis in prostate cancer: Emerging therapeutic strategies. Nat. Rev. Clin. Oncol. 2011, 8, 357-368
5. Heidenreich, A. Bisphosphonates in the management of metastatic prostate cancer. Oncology 2003, 65, 5-11
6. Weilbaecher, K.N.; Guise, T.A.; McCauley, L.K. Cancer to bone: A fatal attraction. Nat. Rev. Cancer 2011, 11, 411-425
7. Morgans, A.K.; Smith, M.R. Bone-targeted agents: Preventing skeletal complications in prostate cancer. Urol. Clin. North Am. 2012, 39, 533-546
8. Langdon, S.P. Animal modeling of cancer pathology and studying tumor response to therapy. Curr. Drug Targets 2012, 13, 1535-1547
9. Waters, D.J.; Hayden, D.W.; Bell, F.W.; Klausner, J.S.; Qian, J.; Bostwick, D.G. Prostatic intraepithelial neoplasia in dogs with spontaneous prostate cancer. Prostate 1997, 30, 92-97
10. Gamlem, H.; Nordstoga, K.; Glattre, E. Canine neoplasia-Introductory paper. APMIS. Suppl. 2008, 125, 5-18
11. Rosol, T.J.; Tannehill-Gregg, S.H.; LeRoy, B.E.; Mandl, S.; Contag, C.H. Animal models of bone metastasis. Cancer 2003, 97, 748-757
12. Smith, J. Canine prostatic disease: A review of anatomy, pathology, diagnosis, and treatment. Theriogenology 2008, 70, 375-383
13. Waters, D.J.; Bostwick, D.G. Prostatic intraepithelial neoplasia occurs spontaneously in the canine prostate. J. Urol. 1997, 157, 713-716
14. Madewell, B.R.; Gandour-Edwards, R.; DeVere White, R.W. Canine prostatic intraepithelial neoplasia: Is the comparative model relevant? Prostate 2004, 58, 314-317
15. Teske, E.; Naan, E.C.; van Dijk, E.M.; van Garderen, E.; Schalken, J.A. Canine prostate carcinoma: Epidemiological evidence of an increased risk in castrated dogs. Mol. Cell. Endocrinol. 2002, 197, 251-255
16. Moulay, M.; Liu, W.; Willenbrock, S.; Sterenczak, K.A.; Carlson, R.; Ngezahayo, A.; Murua Escobar, H.; Nolte, I. Evaluation of stem cell marker gene expression in canine prostate carcinoma-and prostate cyst-derived cell lines. Anticancer Res. 2013, 33, 5421-5431
17. Sharifi, N. Mechanisms of androgen receptor activation in castration-resistant prostate cancer. Endocrinology 2013, 154, 4010-4017
18. Derleth, C.L.; Yu, E.Y. Targeted therapy in the treatment of castration-resistant prostate cancer. Oncology (Williston Park) 2013, 27, 620-628
19. Gallardo, F.; Mogas, T.; Baro, T.; Rabanal, R.; Morote, J.; Abal, M.; Reventos, J.; Lloreta, J. Expression of androgen, oestrogen alpha and beta, and progesterone receptors in the canine prostate: Differences between normal, inflamed, hyperplastic and neoplastic glands. J. Comp. Pathol. 2007, 136, 1-8
20. Leav, I.; Schelling, K.H.; Adams, J.Y.; Merk, F.B.; Alroy, J. Role of canine basal cells in postnatal prostatic development, induction of hyperplasia, and sex hormone-stimulated growth; and the ductal origin of carcinoma. Prostate 2001, 48, 210-224
21. Genega, E.M.; Hutchinson, B.; Reuter, V.E.; Gaudin, P.B. Immunophenotype of high-grade prostatic adenocarcinoma and urothelial carcinoma. Mod. Pathol. 2000, 13, 1186-1191
22. Gobello, C.; Castex, G.; Corrada, Y. Serum and seminal markers in the diagnosis of disorders of the genital tract of the dog: A mini-review. Theriogenology 2002, 57, 1285-1291
23. LeRoy, B.E.; Nadella, M.V.; Toribio, R.E.; Leav, I.; Rosol, T.J. Canine prostate carcinomas express markers of urothelial and prostatic differentiation. Vet. Pathol. 2004, 41, 131-140
24. Aggarwal, S.; Ricklis, R.M.; Williams, S.A.; Denmeade, S.R. Comparative study of psma expression in the prostate of mouse, dog, monkey, and human. Prostate 2006, 66, 903-910
25. Wu, L.Y.; Johnson, J.M.; Simmons, J.K.; Mendes, D.E.; Geruntho, J.J.; Liu, T.; Dirksen, W.P.; Rosol, T.J.; Davis, W.C.; Berkman, C.E. Biochemical characterization of prostate-specific membrane antigen from canine prostate carcinoma cells. Prostate 2014, 74, 451-457
26. Paner, G.P.; Luthringer, D.J.; Amin, M.B. Best practice in diagnostic immunohistochemistry: Prostate carcinoma and its mimics in needle core biopsies. Arch. Pathol. Lab. Med. 2008, 132, 1388-1396
27. McEntee, M.; Isaacs, W.; Smith, C. Adenocarcinoma of the canine prostate: Immunohistochemical examination for secretory antigens. Prostate 1987, 11, 163-170
28. LeRoy, B.; Painter, A.; Sheppard, H.; Popiolek, L.; Samuel-Foo, M.; Andacht, T.M. Protein expression profiling of normal and neoplastic canine prostate and bladder tissue. Vet. Comp. Oncol. 2007, 5, 119-130
29. Chen, Y.; Scher, H.I. Prostate cancer in 2011: Hitting old targets better and identifying new targets. Nat. Rev. Clin. Oncol. 2012, 9, 70-72
30. Meuten, D.J. Tumors in Domestic Animals, 4th ed.; Wiley-Blackwell: Ames, IA, USA, 2002
31. Cornell, K.K.; Bostwick, D.G.; Cooley, D.M.; Hall, G.; Harvey, H.J.; Hendrick, M.J.; Pauli, B.U.; Render, J.A.; Stoica, G.; Sweet, D.C.; et al. Clinical and pathologic aspects of spontaneous canine prostate carcinoma: A retrospective analysis of 76 cases. Prostate 2000, 45, 173-183
32. Valkenburg, K.C.; Williams, B.O. Mouse models of prostate cancer. Prostate Cancer 2011, 2011, doi:10.1155/2011/895238
33. LeRoy, B.E.; Bahnson, R.R.; Rosol, T.J. New bone formation in nude mouse calvaria induced by canine prostate tissue. Mol. Cell. Endocrinol. 2002, 197, 257-263
34. LeRoy, B.E.; Sellers, R.S.; Rosol, T.J. Canine prostate stimulates osteoblast function using the endothelin receptors. Prostate 2004, 59, 148-156
35. Heidegger, I.; Massoner, P.; Eder, I.E.; Pircher, A.; Pichler, R.; Aigner, F.; Bektic, J.; Horninger, W.; Klocker, H. Novel therapeutic approaches for the treatment of castration-resistant prostate cancer. J. Steroid Biochem. Mol. Biol. 2013, 138, 248-256
36. Rove, K.O.; Crawford, E.D. Evolution of treatment options for patients with CRPC and bone metastases: Bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Oncology (Williston Park) 2011, 25, 1362-1370, 1375-1381, 1387
37. Pinto, A.; Merino, M.; Zamora, P.; Redondo, A.; Castelo, B.; Espinosa, E. Targeting the endothelin axis in prostate carcinoma. Tumour Biol. 2012, 33, 421-426
38. Roh, M.; Abdulkadir, S.A. Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse? Cancer Biol. Ther. 2010, 9, 615-617
39. Shao, N.; Wang, Y.; Jiang, W.Y.; Qiao, D.; Zhang, S.G.; Wu, Y.; Zhang, X.X.; Wang, J.L.; Ding, Y.; Feng, N.H. Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer. Int. J. Cancer. 2013, 133, 1743-1750
40. Ishizaka, K.; Azuma, H.; Matsubara, O.; Kitahara, S.; Oshima, H. Production of endothelin by canine prostatic epithelial cells and its stimulatory effects on their growth. J. Androl. 1999, 20, 529-536
41. Blomme, E.A.; Sugimoto, Y.; McCauley, L.K.; Lin, Y.C.; Capen, C.C.; Rosol, T.J. Stromal and epithelial cells of the canine prostate express parathyroid hormone-related protein, but not the pth/pthrp receptor. Prostate 1998, 36, 110-120
42. Anidjar, M.; Villette, J.M.; Devauchelle, P.; Delisle, F.; Cotard, J.P.; Billotey, C.; Cochand-Priollet, B.; Copin, H.; Barnoux, M.; Triballeau, S.; et al. In vivo model mimicking natural history of dog prostate cancer using DPC-1, a new canine prostate carcinoma cell line. Prostate 2001, 46, 2-10
43. Eaton, C.L.; Pierrepoint, C.G. Growth of a spontaneous canine prostatic adenocarcinoma in vivo and in vitro: Isolation and characterization of a neoplastic prostatic epithelial cell line, CPA 1. Prostate 1988, 12, 129-143
44. LeRoy, B.E.; Thudi, N.K.; Nadella, M.V.; Toribio, R.E.; Tannehill-Gregg, S.H.; van Bokhoven, A.; Davis, D.; Corn, S.; Rosol, T.J. New bone formation and osteolysis by a metastatic, highly invasive canine prostate carcinoma xenograft. Prostate 2006, 66, 1213-1222
45. Thudi, N.K.; Shu, S.T.; Martin, C.K.; Lanigan, L.G.; Nadella, M.V.; Van Bokhoven, A.; Werbeck, J.L.; Simmons, J.K.; Murahari, S.; Kisseberth, W.C.; et al. Development of a brain metastatic canine prostate cancer cell line. Prostate 2011, 71, 1251-1263
46. Fork, M.A.; Murua Escobar, H.; Soller, J.T.; Sterenczak, K.A.; Willenbrock, S.; Winkler, S.; Dorsch, M.; Reimann-Berg, N.; Hedrich, H.J.; Bullerdiek, J.; et al. Establishing an in vivo model of canine prostate carcinoma using the new cell line ct1258. BMC Cancer 2008, 8, doi:10.1186/1471-2407-8-240
47. Anidjar, M.; Scarlata, E.; Cury, F.L.; Rocha, J.; Hamel, L.; Luz, M.; Chevalier, S. Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men. Prostate 2012, 72, 752-761
48. Li, X.; Liao, J.; Park, S.I.; Koh, A.J.; Sadler, W.D.; Pienta, K.J.; Rosol, T.J.; McCauley, L.K. Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone. Bone 2011, 48, 1354-1361
49. Liao, J.; Li, X.; Koh, A.J.; Berry, J.E.; Thudi, N.; Rosol, T.J.; Pienta, K.J.; McCauley, L.K. Tumor expressed pthrp facilitates prostate cancer-induced osteoblastic lesions. Int. J. Cancer. 2008, 123, 2267-2278
50. Wise-Milestone, L.; Akens, M.K.; Rosol, T.J.; Hojjat, S.P.; Grynpas, M.D.; Whyne, C.M. Evaluating the effects of mixed osteolytic/osteoblastic metastasis on vertebral bone quality in a new rat model. J. Orthop. Res. 2012, 30, 817-823
51. Schade, G.R.; Keller, J.; Ives, K.; Cheng, X.; Rosol, T.J.; Keller, E.; Roberts, W.W. Histotripsy focal ablation of implanted prostate tumor in an ACE-1 canine cancer model. J. Urol. 2012, 188, 1957-1964
52. Halvorson, K.G.; Kubota, K.; Sevcik, M.A.; Lindsay, T.H.; Sotillo, J.E.; Ghilardi, J.R.; Rosol, T.J.; Boustany, L.; Shelton, D.L.; Mantyh, P.W. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 2005, 65, 9426-9435
53. Halvorson, K.G.; Sevcik, M.A.; Ghilardi, J.R.; Rosol, T.J.; Mantyh, P.W. Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer. Clin. J. Pain 2006, 22, 587-600
54. Thudi, N.K.; Martin, C.K.; Murahari, S.; Shu, S.T.; Lanigan, L.G.; Werbeck, J.L.; Keller, E.T.; McCauley, L.K.; Pinzone, J.J.; Rosol, T.J. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate 2011, 71, 615-625
55. Simmons, J.K.; Dirksen, W.P.; Hildreth, B.E., 3rd; Dorr, C.; Williams, C.; Thomas, R.; Breen, M.; Toribio, R.E.; Rosol, T.J. Canine prostate cancer cell line (probasco) produces osteoblastic metastases in vivo. Prostate 2014, PROS-14-178, in press
56. Navone, N.M.; Logothetis, C.J.; von Eschenbach, A.C.; Troncoso, P. Model systems of prostate cancer: Uses and limitations. Cancer Metastasis Rev. 1998, 17, 361-371
57. Keller, J.M.; Schade, G.R.; Ives, K.; Cheng, X.; Rosol, T.J.; Piert, M.; Siddiqui, J.; Roberts, W.W.; Keller, E.T. A novel canine model for prostate cancer. Prostate 2013, 73, 952-959
58. Lee, Y.P.; Schwarz, E.M.; Davies, M.; Jo, M.; Gates, J.; Zhang, X.; Wu, J.; Lieberman, J.R. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 2002, 62, 5564-5570
59. Wu, T.T.; Sikes, R.A.; Cui, Q.; Thalmann, G.N.; Kao, C.; Murphy, C.F.; Yang, H.; Zhau, H.E.; Balian, G.; Chung, L.W. Establishing human prostate cancer cell xenografts in bone: Induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines. Int. J. Cancer 1998, 77, 887-894
60. Yang, M.; Jiang, P.; Sun, F.X.; Hasegawa, S.; Baranov, E.; Chishima, T.; Shimada, H.; Moossa, A.R.; Hoffman, R.M. A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res. 1999, 59, 781-786
61. Nemeth, J.A.; Harb, J.F.; Barroso, U., Jr.; He, Z.; Grignon, D.J.; Cher, M.L. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res. 1999, 59, 1987-1993
62. Yonou, H.; Yokose, T.; Kamijo, T.; Kanomata, N.; Hasebe, T.; Nagai, K.; Hatano, T.; Ogawa, Y.; Ochiai, A. Establishment of a novel species-and tissue-specific metastasis model of human prostate cancer in humanized non-obese diabetic/severe combined immunodeficient mice engrafted with human adult lung and bone. Cancer Res. 2001, 61, 2177-2182
63. Pettaway, C.A.; Pathak, S.; Greene, G.; Ramirez, E.; Wilson, M.R.; Killion, J.J.; Fidler, I.J. Selection of highly metastatic variants of different human prostatic carcinomas using orthotopic implantation in nude mice. Clin. Cancer Res. 1996, 2, 1627-1636
64. Kozlowski, J.M.; Fidler, I.J.; Campbell, D.; Xu, Z.L.; Kaighn, M.E.; Hart, I.R. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res. 1984, 44, 3522-3529
65. Parkins, G.E.; Klufio, G.O. Prostate cancer metastasis to the mandible: Case report. East Afr. Med. J. 2009, 86, 251-252
66. Craft, N.; Chhor, C.; Tran, C.; Belldegrun, A.; DeKernion, J.; Witte, O.N.; Said, J.; Reiter, R.E.; Sawyers, C.L. Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process. Cancer Res. 1999, 59, 5030-5036
67. Davies, M.R.; Lee, Y.P.; Lee, C.; Zhang, X.; Afar, D.E.; Lieberman, J.R. Use of a scid mouse model to select for a more aggressive strain of prostate cancer. Anticancer Res. 2003, 23, 2245-2252
68. Tsingotjidou, A.S.; Zotalis, G.; Jackson, K.R.; Sawyers, C.; Puzas, J.E.; Hicks, D.G.; Reiter, R.; Lieberman, J.R. Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res. 2001, 21, 971-978
69. Yonou, H.; Kanomata, N.; Goya, M.; Kamijo, T.; Yokose, T.; Hasebe, T.; Nagai, K.; Hatano, T.; Ogawa, Y.; Ochiai, A. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice. Cancer Res. 2003, 63, 2096-2102
70. Dias, S.J.; Li, K.; Rimando, A.M.; Dhar, S.; Mizuno, C.S.; Penman, A.D.; Levenson, A.S. Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation and growth in prostate cancer xenografts. Prostate 2013, 73, 1135-1146
71. Scatena, C.D.; Hepner, M.A.; Oei, Y.A.; Dusich, J.M.; Yu, S.F.; Purchio, T.; Contag, P.R.; Jenkins, D.E. Imaging of bioluminescent LNCaP-luc-M6 tumors: A new animal model for the study of metastatic human prostate cancer. Prostate 2004, 59, 292-303
72. Thalmann, G.N.; Anezinis, P.E.; Chang, S.M.; Zhau, H.E.; Kim, E.E.; Hopwood, V.L.; Pathak, S.; von Eschenbach, A.C.; Chung, L.W. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994, 54, 2577-2581
73. Tso, C.L.; McBride, W.H.; Sun, J.; Patel, B.; Tsui, K.H.; Paik, S.H.; Gitlitz, B.; Caliliw, R.; van Ophoven, A.; Wu, L.; et al. Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. Cancer J. 2000, 6, 220-233
74. Navone, N.M.; Olive, M.; Ozen, M.; Davis, R.; Troncoso, P.; Tu, S.M.; Johnston, D.; Pollack, A.; Pathak, S.; von Eschenbach, A.C.; et al. Establishment of two human prostate cancer cell lines derived from a single bone metastasis. Clin. Cancer Res. 1997, 3, 2493-2500
75. Yang, J.; Fizazi, K.; Peleg, S.; Sikes, C.R.; Raymond, A.K.; Jamal, N.; Hu, M.; Olive, M.; Martinez, L.A.; Wood, C.G.; et al. Prostate cancer cells induce osteoblast differentiation through a cbfa1-dependent pathway. Cancer Res. 2001, 61, 5652-5659
76. Goya, M.; Miyamoto, S.; Nagai, K.; Ohki, Y.; Nakamura, K.; Shitara, K.; Maeda, H.; Sangai, T.; Kodama, K.; Endoh, Y.; et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res. 2004, 64, 6252-6258
77. Zhao, X.Y.; Malloy, P.J.; Krishnan, A.V.; Swami, S.; Navone, N.M.; Peehl, D.M.; Feldman, D. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med. 2000, 6, 703-706
78. Hara, T.; Nakamura, K.; Araki, H.; Kusaka, M.; Yamaoka, M. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline. Cancer Res. 2003, 63, 5622-5628
79. Zhao, X.Y.; Boyle, B.; Krishnan, A.V.; Navone, N.M.; Peehl, D.M.; Feldman, D. Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J. Urol. 1999, 162, 2192-2199
80. Liu, X.H.; Kirschenbaum, A.; Yao, S.; Liu, G.; Aaronson, S.A.; Levine, A.C. Androgen-induced wnt signaling in preosteoblasts promotes the growth of MDA-PCa-2b human prostate cancer cells. Cancer Res. 2007, 67, 5747-5753
81. Pretlow, T.G.; Wolman, S.R.; Micale, M.A.; Pelley, R.J.; Kursh, E.D.; Resnick, M.I.; Bodner, D.R.; Jacobberger, J.W.; Delmoro, C.M.; Giaconia, J.M.; et al. Xenografts of primary human prostatic carcinoma. J. Natl. Cancer Inst. 1993, 85, 394-398
82. Holleran, J.L.; Miller, C.J.; Culp, L.A. Tracking micrometastasis to multiple organs with lacZ-tagged CWR22R prostate carcinoma cells. J. Histochem. Cytochem. 2000, 48, 643-651
83. Zhau, H.Y.; Chang, S.M.; Chen, B.Q.; Wang, Y.; Zhang, H.; Kao, C.; Sang, Q.A.; Pathak, S.J.; Chung, L.W. Androgen-repressed phenotype in human prostate cancer. Proc. Natl. Acad. Sci. U.S.A 1996, 93, 15152-15157
84. Corey, E.; Quinn, J.E.; Buhler, K.R.; Nelson, P.S.; Macoska, J.A.; True, L.D.; Vessella, R.L. LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate 2003, 55, 239-246
85. Ellis, W.J.; Vessella, R.L.; Buhler, K.R.; Bladou, F.; True, L.D.; Bigler, S.A.; Curtis, D.; Lange, P.H. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin. Cancer Res. 1996, 2, 1039-1048
86. Corey, E.; Quinn, J.E.; Bladou, F.; Brown, L.G.; Roudier, M.P.; Brown, J.M.; Buhler, K.R.; Vessella, R.L. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002, 52, 20-33
87. Corey, E.; Quinn, J.E.; Vessella, R.L. A novel method of generating prostate cancer metastases from orthotopic implants. Prostate 2003, 56, 110-114
88. Pinthus, J.H.; Waks, T.; Schindler, D.G.; Harmelin, A.; Said, J.W.; Belldegrun, A.; Ramon, J.; Eshhar, Z. WISH-PC2: A unique xenograft model of human prostatic small cell carcinoma. Cancer Res. 2000, 60, 6563-6567
89. Lee, C.H.; Akin-Olugbade, O.; Kirschenbaum, A. Overview of prostate anatomy, histology, and pathology. Endocrinol. Metab. Clin. North Am. 2011, 40, 565-575
90. Shappell, S.B.; Thomas, G.V.; Roberts, R.L.; Herbert, R.; Ittmann, M.M.; Rubin, M.A.; Humphrey, P.A.; Sundberg, J.P.; Rozengurt, N.; Barrios, R.; et al. Prostate pathology of genetically engineered mice: Definitions and classification. The consensus report from the bar harbor meeting of the mouse models of human cancer consortium prostate pathology committee. Cancer Res. 2004, 64, 2270-2305
91. Kasper, S. Survey of genetically engineered mouse models for prostate cancer: Analyzing the molecular basis of prostate cancer development, progression, and metastasis. J. Cell. Biochem. 2005, 94, 279-297
92. Berman-Booty, L.D.; Sargeant, A.M.; Rosol, T.J.; Rengel, R.C.; Clinton, S.K.; Chen, C.S.; Kulp, S.K. A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in tramp mice. Toxicol. Pathol. 2012, 40, 5-17
93. Berman-Booty, L.D.; Chu, P.C.; Thomas-Ahner, J.M.; Bolon, B.; Wang, D.; Yang, T.; Clinton, S.K.; Kulp, S.K.; Chen, C.S. Suppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent. Cancer Prev. Res. 2013, 6, 232-241
94. Sargeant, A.M.; Klein, R.D.; Rengel, R.C.; Clinton, S.K.; Kulp, S.K.; Kashida, Y.; Yamaguchi, M.; Wang, X.; Chen, C.S. Chemopreventive and bioenergetic signaling effects of PDK1/Akt pathway inhibition in a transgenic mouse model of prostate cancer. Toxicol. Pathol. 2007, 35, 549-561
95. Patel, S.J.; Molinolo, A.A.; Gutkind, S.; Crawford, N.P. Germline genetic variation modulates tumor progression and metastasis in a mouse model of neuroendocrine prostate carcinoma. PLoS One 2013, 8, doi:10.1371/journal.pone.0061848
96. Gingrich, J.R.; Barrios, R.J.; Morton, R.A.; Boyce, B.F.; DeMayo, F.J.; Finegold, M.J.; Angelopoulou, R.; Rosen, J.M.; Greenberg, N.M. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996, 56, 4096-4102
97. Hensley, P.J.; Kyprianou, N. Modeling prostate cancer in mice: Limitations and opportunities. J. Androl. 2012, 33, 133-144
98. Roy-Burman, P.; Wu, H.; Powell, W.C.; Hagenkord, J.; Cohen, M.B. Genetically defined mouse models that mimic natural aspects of human prostate cancer development. Endocr.-Relat. Cancer 2004, 11, 225-254
99. Gupta, S.; Hastak, K.; Ahmad, N.; Lewin, J.S.; Mukhtar, H. Inhibition of prostate carcinogenesis in tramp mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. USA 2001, 98, 10350-10355
100. Klezovitch, O.; Chevillet, J.; Mirosevich, J.; Roberts, R.L.; Matusik, R.J.; Vasioukhin, V. Hepsin promotes prostate cancer progression and metastasis. Cancer Cell 2004, 6, 185-195
101. Garabedian, E.M.; Humphrey, P.A.; Gordon, J.I. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc. Natl. Acad. Sci. USA 1998, 95, 15382-15387
102. Tu, W.H.; Thomas, T.Z.; Masumori, N.; Bhowmick, N.A.; Gorska, A.E.; Shyr, Y.; Kasper, S.; Case, T.; Roberts, R.L.; Shappell, S.B.; et al. The loss of tgf-beta signaling promotes prostate cancer metastasis. Neoplasia 2003, 5, 267-277
103. Ding, Z.; Wu, C.J.; Jaskelioff, M.; Ivanova, E.; Kost-Alimova, M.; Protopopov, A.; Chu, G.C.; Wang, G.; Lu, X.; Labrot, E.S.; et al. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012, 148, 896-907
104. Wang, S.; Gao, J.; Lei, Q.; Rozengurt, N.; Pritchard, C.; Jiao, J.; Thomas, G.V.; Li, G.; Roy-Burman, P.; Nelson, P.S.; et al. Prostate-specific deletion of the murine pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4, 209-221
105. Perez-Stable, C.; Altman, N.H.; Mehta, P.P.; Deftos, L.J.; Roos, B.A. Prostate cancer progression, metastasis, and gene expression in transgenic mice. Cancer Res. 1997, 57, 900-906
106. Cai, Y.; Kregel, S.; Vander Griend, D.J. Formation of human prostate epithelium using tissue recombination of rodent urogenital sinus mesenchyme and human stem cells. J. Vis. Exp. 2013, 22, doi:10.3791/50327
107. Buttyan, R. The mouse prostate reconstitution model of prostate diseases. Prostate 1997, 33, 164-165
108. Thompson, T.C.; Timme, T.L.; Park, S.H.; Yang, G.; Ren, C. Mouse prostate reconstitution model system: A series of in vivo and in vitro models for benign and malignant prostatic disease. Prostate 2000, 43, 248-254
109. Cunha, G.R.; Hayward, S.W.; Wang, Y.Z. Role of stroma in carcinogenesis of the prostate. Differentiation 2002, 70, 473-485
110. Thompson, T.C.; Park, S.H.; Timme, T.L.; Ren, C.; Eastham, J.A.; Donehower, L.A.; Bradley, A.; Kadmon, D.; Yang, G. Loss of p53 function leads to metastasis in ras + myc-initiated mouse prostate cancer. Oncogene 1995, 10, 869-879
111. Park, S.I.; Kim, S.J.; McCauley, L.K.; Gallick, G.E. Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr. Protoc. Pharmacol. 2010, doi:10.1002/0471141755.ph1415s51
112. Blouin, S.; Basle, M.F.; Chappard, D. Rat models of bone metastases. Clin. Exp. Metastasis 2005, 22, 605-614
113. Pollard, M.; Suckow, M.A. Hormone-refractory prostate cancer in the lobund-wistar rat. Exp. Biol. Med. 2005, 230, 520-526
114. Liepe, K.; Geidel, H.; Haase, M.; Hakenberg, O.W.; Runge, R.; Kotzerke, J. New model for the induction of osteoblastic bone metastases in rat. Anticancer Res. 2005, 25, 1067-1073
115. Geldof, A.A.; Rao, B.R. Prostatic tumor (r3327) skeletal metastasis. Prostate 1990, 16, 279-290
116. Haq, M.; Goltzman, D.; Tremblay, G.; Brodt, P. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res. 1992, 52, 4613-4619
117. Blomme, E.A.; Dougherty, K.M.; Pienta, K.J.; Capen, C.C.; Rosol, T.J.; McCauley, L.K. Skeletal metastasis of prostate adenocarcinoma in rats: Morphometric analysis and role of parathyroid hormone-related protein. Prostate 1999, 39, 187-197
118. Tennant, T.R.; Kim, H.; Sokoloff, M.; Rinker-Schaeffer, C.W. The dunning model. Prostate 2000, 43, 295-302
119. Koutsilieris, M. PA-III rat prostate adenocarcinoma cells (review). In Vivo 1992, 6, 199-203
120. Lorente, D.; de Bono, J.S. Molecular alterations and emerging targets in castration resistant prostate cancer. Eur. J. Cancer 2014, 50, 753-764